Table S1. Baseline clinical characteristics and medications, initiated medications, laboratory parameters echocardiographic features of the patients grouped according to change in ASCVD risk score during 1-year after enrolment

	Group 1 Decrease in ASCVD at 1-year (n = 192)	Group 2 Increase in ASCVD at 1-year (n = 50)	*P*-value
Age, years	57 (7)	60 (7)	0.056
Gender, male %	99 (51.6)	25 (50.0)	0.844
Body mass index, kg/m^2	28.8 (25.6–32.4)	28.3 (25.1–31.4)	0.297
Systolic blood pressure, mm Hg	144.0 (134.0–153.0)	132.0 (121.0–144.0)	<0.001
Diastolic blood pressure, mm Hg	83.0 (74.0–92.0)	77.0 (71.0–88.0)	0.049
Hypertension	139 (72.4)	28 (56.0)	0.029
Diabetes mellitus	81 (42.2)	28 (56.0)	0.081
Hyperlipidemia	42 (21.9)	7 (14.0)	0.202
Smoking	93 (48.4)	19 (38.0)	0.185
Heart rate, beat per minute	76.0 (69.0–82.0)	78.0 (71.0–83.0)	0.516
Left ventricle ejection fraction, %	61.0 (60.0–64.0)	61.0 (60.0–64.0)	0.866
Left atrial volume index, ml/m^2	29.6 (7.7)	31.7 (8.9)	0.109
Creatinine, mg/dl	0.81 (0.75–0.93)	0.82 (0.74–0.94)	0.839
Total-Cholesterol, mg/dl	219.0 (42.0)	218.0 (45.0)	0.841
LDL-Cholesterol, mg/dl	138.0 (42.0)	138.0 (42.0)	0.785
HDL-Cholesterol, mg/dl	42.0 (37.0–49.0)	46.0 (40.0–52.0)	0.023
Triglyceride, mg/dl	154.0 (108.0–203.0)	132.0 (98.0–176.0)	0.097

Hs-CRP, mg/dl	0.001 (0.001–0.251)	0.001 (0.001–0.300)	0.246
Hs-Troponin, ng/ml	0.002 (0.001–0.003)	0.002 (0.001–0.003)	0.843
HbA1c, %	6.0 (5.7–6.4)	6.2 (5.8–6.6)	0.017
Baseline medications			
Antiplatelet drugs	38 (19.8)	8 (16.0)	0.536
Statin	10 (5.2)	2 (4.0)	1.000
ACE inhibitors/ARBs	113 (58.9)	18 (36.0)	0.004
Calcium channel inhibitors	43 (22.4)	9 (18.0)	0.493
Beta blockers	39 (20.3)	9 (18.0)	0.712
Diuretics	16 (8.3)	5 (10.0)	0.778
Oral antidiabetic drugs	68 (35.4)	19 (38.0)	0.735
Insulin	12 (6.3)	5 (10.0)	0.357
Initiated medications during 1-year follow-up			
Antiplatelet drugs	0 (0.0)	0 (0.0)	1.000
Statin	139 (72.4)	34 (68.0)	0.543
ACE inhibitors/ARBs	5 (2.6)	2 (4.0)	0.636
Calcium channel inhibitors	23 (12.0)	8 (16.0)	0.459
Beta blockers	12 (6.3)	3 (6.0)	1.000
Diuretics	6 (3.1)	1 (2.0)	1.000
Oral antidiabetic drugs	1 (0.5)	1 (2.0)	0.371
Insulin	0 (0.0)	1 (2.0)	0.207
ASCVD score at admission	14.9 (9.3–21.3)	13.4 (10.1–20.3)	0.511
ASCVD score at 1-year	12.3 (7.6–17.5)	15.5 (11.8–23.2)	0.001
ΔASCVD score	–2.2 (–3.8– –1.1)	1.3 (0.7–2.6)	<0.001

Data were presented as mean (standard deviation [SD]) for normally distributed data, and as median (interquartile range) for continuous variables that were not normally distributed. Categorical data was presented as n (%).

Abbreviations: ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blockers; ASCVD, atherosclerotic cardiovascular disease; HbA1c, Hemoglobin A1c; HDL, high-density lipoprotein; Hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein